← brief for 2026-09-08 · Slowing decline

Targeting MicroRNA-21 in Chronic Kidney Disease: Lessons from the Lademirsen Story

Key takeaways

A look back at lademirsen, a drug built to block a molecule called microRNA-21 that drives kidney scarring. Its trial did not pan out, and the authors walk through what went wrong and what drug developers should take from it. This is commentary on past work, not a new study, so there are no fresh results here.

Who did this work

Verica Stanković Popović (University of Belgrade) · Aleksandar Sič (University of Belgrade) · Selena Gajić (Centar za Promociju Nauke) · Dušan Vićentijević (Centar za Promociju Nauke) · Ana Bontić (University of Belgrade) · Jelena Pavlović (University of Belgrade) · Aleksandra Kezić (University of Belgrade) · Marko Baralić (University of Belgrade)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-07
https://doi.org/10.3390/medsci14050547